IMPI (Mexico's patent and trademark office) has 133 thousand unresolved filings and will hire 500 examiners; the backlog is concentrated in biotechnology and chemistry

Strategic interpretation

Systemic tension: innovation capital moves in cycles of months and state patent examination in cycles of years. The push comes from record demand for industrial property protection; the resistance comes from an examining apparatus of 112 people for a country that declares itself an innovation destination. The winner under the status quo is the large company with lawyers and the international route (PCT), which can wait; the loser is the technology-based SME whose funding round will not wait five years for examination to begin. The figure comes from the State itself, against its own narrative interest, which strengthens it. Who it affects: the Mexican technology-based company in agrobiotechnology, pharma or materials that needs the patent to negotiate with investors or with an anchor company. Second order: if examination does not arrive in time, the protection strategy migrates to trade secrets or to filing first in the United States — and the Mexican patent system loses exactly the users that innovation policy says it wants to attract. Worldview: innovating is assumed to mean inventing, and the filing process a neutral accessory. The industrial property registry is market infrastructure: without timely examination, an invention is not a negotiable asset. What to watch: whether the hiring of the 500 examiners materializes in budget and positions during 2026-2027, and whether first-examination times in biotechnology and chemistry fall in the 2027 annual reports of IMPI (Mexico's patent and trademark office).